Helixgate

Helixgate

Uncategorized

Nektar’s long-term mid-stage alopecia data fuels Phase 3 plans

Published

on

Nektar Therapeutics’ data from the extension phase of a failed Phase 2b alopecia trial just about met Wall Street analyst expectations, helping the biotech’s ambitions to move forward in the indication.

The company’s rezpegaldesleukin, more …

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Boehringer Ingelheim to expand its AI footprint in UK in £150M investment

Published

on

LONDON – Boehringer Ingelheim is growing its artificial intelligence arm to the UK by building a new hub in central London and investing £150 million over the next 10 years.

The AI hub will be …

Continue Reading

Uncategorized

Agenus cancer cocktail records 0% response rate, missing midstage goal

Agenus cancer cocktail records 0% response rate, missing midstage goal

Published

on

An investigational cocktail was tied to a 0% overall response rate in patients with gastroesophageal cancer, but developers Agenus and MiNK Therapeutics aren’t giving up on the program just yet.​ ​Read More

Continue Reading

Uncategorized

Novo’s late-stage sickle cell win piles pressure on competitors

Published

on

Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating “separation amongst PK class candidates,” Truist analysts said on Monday. Novo plans to seek FDA approval in the back half of 2026.

Continue Reading
Advertisement

Trending